Skip to main content

Site notifications

(Approval lapsed) Amoxicillin and clavulanate potassium tablets, USP 875mg/125mg (Micro Labs)

Section 19A approved medicine
(Approval lapsed) Amoxicillin and clavulanate potassium tablets, USP 875mg/125mg (Micro Labs)
Section 19A approval holder
Pro Pharmaceuticals Group Pty Ltd ABN: 20 605 457 430
Phone
1300 077 674
Approved until
Status
Expired
Medicines in short supply/unavailable
AMCLAVOX DUO FORTE 875/125, amoxicillin (as trihydrate) 875 mg and clavulanic acid (as potassium) 125 mg tablets blister pack AUST R: 288119
Indication(s)

AMOXICILLIN AND CLAVULANATE POTASSIUM tablets are indicated for short term treatment of bacterial infections at the following sites when caused by sensitive organisms.

  • Urinary Tract Infections (uncomplicated and complicated)
  • Lower Respiratory Tract Infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis
  • Upper Respiratory Tract Infections, such as sinusitis, otitis media and recurrent tonsillitis
  • Skin and Skin Structure Infection

Appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to AMOXICILLIN AND CLAVULANATE POTASSIUM tablets, however, when there is reason to believe an infection may involve any of the β-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. Once these results are known, therapy should be adjusted if appropriate. The treatment of mixed infections caused by amoxicillin susceptible organisms and β-lactamase producing organisms susceptible to AMOXICILLIN AND CLAVULANATE POTASSIUM tablets should not require the addition of another antibiotic due to the amoxicillin content of these products.

Images
Picture of Amoxicillin and clavulanate potassium tablets, USP 875mg/125mg (Micro Labs)

Help us improve the Therapeutic Goods Administration site